Ehave Inc (EHVVF)

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report from Roth Capital is no exception. On April 19, Roth Capital analyst Elemer Piros issued an industry note outlining the significant upside potential of […]

Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and biomarkers to target the condition. HPPD, (HPPD) or “flashbacks” is the only recognized long-term complication of hallucinogen use. It can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. As psychedelics become more widely accepted, the data and biomarkers from Ehave’s MetaHealthU will enhance research into HPPD, which will assist medical and mental health professionals to diagnose if an individual is genetically predisposed to suffer from the condition.